55501-45-6

Usage

Uses

2-Chloro-4''-nitrobenzanilide (cas# 55501-45-6) is a compound useful in organic synthesis.

InChI:InChI=1/C13H9ClN2O3/c14-12-4-2-1-3-11(12)13(17)15-9-5-7-10(8-6-9)16(18)19/h1-8H,(H,15,17)

Upstream product

• 130340-71-5 N-(p-methylbenzyl)cyclohexanecarboxamide 
• 130340-63-5 N¹-(o-chlorobenzoyl)-N¹,N²-di-(p-nitrophenyl)formamidine 
• 54979-77-0 N-(p-chlorobenzoyl)furfurylamine 
• 130340-59-9 dl-N-(α-phenylpropionyl)-p-methylbenzylamine 
• 100-01-6 4-nitro-aniline 
• 118-91-2 ortho-chlorobenzoic acid 
• 130340-58-8 N,N-bis(p-nitrophenyliminomethyl)-p-nitroaniline 
• 128799-78-0 N¹-(p-chlorobenzoyl)-N¹,N²-di(p-nitrophenyl)formamidine 
• 2232-13-5 N¹,N²-di-(p-nitrophenyl)formamidine 
• 609-65-4 o-chlorobenzoyl chloride 
• 130340-69-1 4-(p-chlorobenzoylamino)-1-butyl acetate 
• 130340-68-0 N-(p-chlorobenzoyl)-2-(p-chlorophenyl)ethylamine 
• 57707-20-7 4-chloro-N-cyclohexylbenzamide 
• 1455-99-8 N-butyl-4-chlorobenzamide 

Downstream Products

• 2011-66-7 2'-chloro-5-nitro-2-aminobenzophenone 
• 897852-11-8 N-(4-(2-chlorobenzamido)phenyl)picolinamide 
• 33238-16-3 3-benzylidene-2-(4-nitrophenyl)isoindol-1-one 
• 113456-71-6 [2-(4-methyl-1-piperidinyl)-5-nitrophenyl]-(2-chlorophenyl)-methanone 
• 86187-94-2 [5-Amino-2-(4-methyl-piperidin-1-yl)-phenyl]-(2-chloro-phenyl)-methanone 
• 54534-72-4 (2-chloro-5-nitrophenyl)(2-chlorophenyl)methanone 
• 100-01-6 4-nitro-aniline 
• 118-91-2 ortho-chlorobenzoic acid 

Relevant academic research and scientific papers

Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments

VEGF/VEGFR-2 signaling plays a critical part in tumor angiogenesis. Inhibition of this pathway has been considered as a promising approach for cancer treatment. In this work, a series of 6,7-dimethoxy-4-anilinoquinazoline derivatives bearing diarylamide moiety were designed, synthesized and evaluated as potent inhibitors of VEGFR-2 kinase. Their in vitro antiproliferation activities against two human cancer cell lines Hep-G2 and MCF-7 have also been determined. Among them, compound 14b exhibited the most potent inhibitory activity against VEGFR-2 with IC50 value of 0.016 ± 0.002 μM and it showed the most potent antiproliferative effect against Hep-G2 and MCF-7 with IC50 values at low-micromolar range. Molecular docking studies revealed that these compounds represented by the most potent compound 14b could bind well to the ATP-binding site of VEGFR-2, which suggested that compound 14b could be a potential anticancer agent targeting VEGFR-2.

Diarylureas and Diarylamides with Oxazolo[5,4-d]pyrimidine Scaffold as Angiogenesis Inhibitors

A series of oxazolopyrimidine-based ureas and amides were designed, synthesized, and biologically evaluated for their antiproliferative and antiangiogenic activities. These compounds were identified to exhibit inhibitory activities against human umbilical vein endothelial cells (HUVEC) in vitro. Among these compounds, compound 22 effectively inhibited the migration and capillary-like tube formation of human umbilical vein endothelial cells. It also exhibited a concentration-dependent inhibition on capillary sprouting from the rat aorta rings. Preliminary mechanistic studies revealed that compound 22 suppressed protein kinases activation, by decreasing PI3K and ERK 1/2 phosphorylation. These results support the further investigation of this class of compounds as potential anticancer agents.

4-substituted anilinoquinazoline derivatives, and preparation method and application thereof

The invention discloses novel 4-substituted anilinoquinazoline derivatives or pharmaceutically acceptable salts thereof, or polymorphic substances, solvates or stereomers of the 4-substituted anilinoquinazoline derivatives, and a preparation method and application thereof. The 4-substituted anilinoquinazoline compounds have favorable inhibition activities for EGFR and VEGFR-2 in a biological test and have obvious effects in an in-vitro anti-human tumor cell proliferation activity test.

Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu4) with CNS exposure in rats

Herein we report the discovery, synthesis, and evaluation of a series of N-(4-acetamido)-phenylpicolinamides as positive allosteric modulators of mGlu4. Compounds from the series show submicromolar potency at both human and rat mGlu4. In addition, pharmacokinetic studies utilizing subcutaneous dosing demonstrated good brain exposure in rats.